JATT II Acquisition Corp filings document the regulatory record of a Cayman Islands SPAC with Nasdaq-listed ordinary shares. The company’s Form 8-K disclosures report its initial public offering, ordinary-share capitalization, material definitive agreements, underwriter over-allotment arrangements and exchange listing under the symbol JATT.
The filing record also identifies governance and issuer-status matters, including emerging growth company status, Section 12(b) registration of the ordinary shares and other public-company disclosures associated with a blank-check company pursuing a business combination.
Balyasny Asset Management L.P. and affiliated entities report beneficial ownership of common stock of JATT II ACQUISITION CORP. Through Atlas Diversified Master Fund, Ltd., they are associated with 500,000 shares of common stock, par value $0.0001 per share.
Based on 8,025,000 shares outstanding as of May 28, 2026, the reporting group may be deemed to beneficially own approximately 6.23% of the class. Each reporting person is listed with sole voting and sole dispositive power over 500,000 shares, and no shared voting or dispositive power. Atlas Diversified Master Fund, Ltd., as the direct holder, has the right to receive dividends and proceeds from any sale of these securities.
Janus Henderson Group Ltd. reports beneficial ownership of 500,000 ordinary shares of JATT II Acquisition Corp., representing 6.2% of the class. The position is held through various affiliated asset managers that exercise investment and/or voting discretion for client accounts referred to as Managed Portfolios.
Janus Henderson has no sole voting or dispositive power over these shares, but shared voting and dispositive power over 500,000 shares. The asset managers disclaim rights to receive dividends or sale proceeds, which belong to the Managed Portfolios. Among these, Janus Henderson Biotech Innovation Master Fund Ltd. alone has the right to receive dividends or proceeds relating to more than five percent of JATT II’s ordinary shares.
JATT II Acquisition Corp., a Cayman Islands SPAC, reported its first results since its April 20, 2026 IPO for the quarter ended June 30, 2026. The company has not generated operating revenues and recorded a net loss of $305,553 for the quarter and $374,346 since inception.
Total assets were $62,339,246, including $60,409,419 of cash and U.S. Treasuries in the trust account and $1,641,241 of cash outside the trust. The IPO raised $60,000,000 from 6,000,000 public shares, with a further $3,000,000 from 300,000 private placement shares.
On June 29, 2026, JATT II signed a Business Combination Agreement with Talawar Tx Inc. Under the proposed merger, each JATT II ordinary share will convert into one share of Talawar common stock at closing, and public shareholders will retain redemption rights for cash equal to their pro rata share of the trust.
The transaction is supported by a committed PIPE financing of $225 million for 22.5 million Talawar shares at $10.00 per share and is subject to multiple closing conditions, including shareholder approvals, Nasdaq listing of Talawar and a minimum available cash condition of $125,000,000.
JATT II Acquisition Corp. reported an administrative share adjustment involving its sponsor. JATT Ventures II L.P., the sponsor, forfeited 225,000 Ordinary Shares to the company at no cost after the remaining portion of the underwriters' over-allotment option expired under the Registration Statement.
The sponsor is the record holder of the securities, and Dr. Someit Sidhu has voting and investment discretion over these shares through his roles in the sponsor entities. He disclaims beneficial ownership except to the extent of his pecuniary interest. Following the forfeiture, 1,800,000 Ordinary Shares are reported as indirectly held.
JATT Ventures II L.P., the sponsor and a 10% owner of JATT II Acquisition Corp., forfeited 225,000 Ordinary Shares to the company at no cost after the remaining portion of the underwriters' over-allotment option expired. Following this restructuring transaction, the sponsor directly holds 1,800,000 Ordinary Shares. Dr. Someit Sidhu has voting and investment discretion over the shares held by the sponsor and disclaims beneficial ownership except to the extent of any pecuniary interest.
Talawar Tx Inc. entered into a business combination agreement with JATT II Acquisition Corp that will result in JATT becoming an indirect wholly-owned subsidiary of Talawar. The companies said the merger is expected to close in the second half of this year and the combined company will operate under the Talawar name and trade on Nasdaq under the ticker TLWR. The announcement states the combined company is expected to receive $285 million from JATT’s IPO proceeds and Talawar’s concurrent financing, including an oversubscribed $225 million PIPE and JATT’s $60 million IPO trust. Talawar plans to advance its lead preclinical asset, TALA-125, into the clinic in the first quarter of next year, with interim phase 1 data expected by the end of next year and a phase 2b proof-of-concept readout targeted for the second half of 2028.
Talawar Tx Inc. and JATT II Acquisition Corp. entered into a Business Combination Agreement on June 29, 2026 to combine, resulting in JATT becoming an indirect wholly‑owned subsidiary of Talawar. The parties intend to file a Form S-4 that will include JATT proxy statements and a prospectus; a definitive proxy/prospectus will be mailed to JATT shareholders after the Registration Statement is declared effective.
The communication emphasizes forward‑looking statements, lists customary transaction risks (including shareholder approvals, financing, Nasdaq listing and clinical development risks), and states that additional information about participants and risks will appear in SEC filings, including JATT’s April 17, 2026 final prospectus and its May 29, 2026 Form 10‑Q.
JATT II Acquisition Corp entered into a Business Combination Agreement with Talawar Tx Inc. and a Merger Sub, under which Merger Sub will merge into JATT and JATT will become a wholly owned subsidiary of Talawar at the Effective Time. The parties agreed to prepare and file a Form S-4 registration statement and hold a JATT shareholders meeting to vote on the Transaction Proposals.
The agreement contemplates a PIPE Financing of 22.5 million shares at $10.00 per share for aggregate proceeds of $225 million, subject to customary closing conditions including Nasdaq listing approval and a Registration Statement declared effective. The Business Combination Agreement includes sponsor and stockholder support agreements, a 12% equity incentive reserve post-Closing, and customary lock-up and registration-rights provisions.
JATT II Acquisition Corp signed a Business Combination Agreement with Talawar Tx Inc. and Talawar Merger Sub to create a Nasdaq-listed biotechnology company focused on bispecific antibodies for immunology and inflammatory diseases. Merger Sub will merge into JATT, which will become a wholly owned subsidiary of Talawar.
The deal is supported by an oversubscribed $225 million PIPE at $10.00 per share for 22.5 million Talawar common shares, alongside approximately $60 million in JATT’s trust, targeting about $285 million of cash at closing before costs and assuming no redemptions. Closing is conditioned on shareholder approvals, Nasdaq listing of Talawar stock, and a minimum Available Cash of $125,000,000. The combined company expects funding to carry lead asset TALA‑125 through a Phase 2b proof‑of‑concept readout in the second half of 2028.
JATT II Acquisition Corp reported its first quarterly results as a newly formed SPAC, posting a net loss of $68,793 from general and administrative costs for the period from January 13, 2026 through March 31, 2026. As of March 31, 2026, the company had total assets of $161,079, all in prepaid and deferred offering costs, and a working capital deficit of $204,792 funded by a related-party promissory note. After quarter-end, JATT II completed its initial public offering of 6,000,000 ordinary shares at $10.00 per share and a private placement of 300,000 shares, raising gross proceeds of $63,000,000, with $60,000,000 placed in a trust account to pursue a business combination within 24 months.